These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 16842476

  • 21. Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes.
    Smeeton F, Shojaee Moradie F, Jones RH, Westergaard L, Haahr H, Umpleby AM, Russell-Jones DL.
    Diabetologia; 2009 Nov; 52(11):2317-23. PubMed ID: 19707744
    [Abstract] [Full Text] [Related]

  • 22. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.
    Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M.
    Diabetes Care; 2001 Feb; 24(2):296-301. PubMed ID: 11213882
    [Abstract] [Full Text] [Related]

  • 23. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials.
    Garber AJ, Clauson P, Pedersen CB, Kølendorf K.
    J Am Geriatr Soc; 2007 Nov; 55(11):1735-40. PubMed ID: 17979896
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
    Dornhorst A, Lüddeke HJ, Koenen C, Meriläinen M, King A, Robinson A, Sreenan S, PREDICTIVE Study Group.
    Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Observational 6-month open-label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal-bolus regimen: 23rd article of the Japan Diabetes Clinical Data Management Study Group (JDDM23).
    Oishi M, Abe N, Yokoyama H, Kuribayashi N, Tomonaga O, Matoba K, Kobayashi M, Japan Diabetes Clinical Data Management Study Group.
    J Int Med Res; 2012 Jan; 40(2):787-97. PubMed ID: 22613444
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes.
    Chacra AR, Kipnes M, Ilag LL, Sarwat S, Giaconia J, Chan J, COMPLETE T1D investigators.
    Diabet Med; 2010 May; 27(5):563-9. PubMed ID: 20536953
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database.
    Laubner K, Molz K, Kerner W, Karges W, Lang W, Dapp A, Schütt M, Best F, Seufert J, Holl RW.
    Diabetes Metab Res Rev; 2014 Jul; 30(5):395-404. PubMed ID: 24302583
    [Abstract] [Full Text] [Related]

  • 34. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
    Valensi P, Cosson E.
    Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
    [Abstract] [Full Text] [Related]

  • 35. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1).
    Hirsch IB, Franek E, Mersebach H, Bardtrum L, Hermansen K.
    Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Insulin detemir: a review of its use in the management of diabetes mellitus.
    Keating GM.
    Drugs; 2012 Dec 03; 72(17):2255-87. PubMed ID: 23110609
    [Abstract] [Full Text] [Related]

  • 38. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR, Gilbert RE, Yue DK.
    Intern Med J; 2005 Sep 03; 35(9):536-42. PubMed ID: 16105155
    [Abstract] [Full Text] [Related]

  • 39. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.
    Health Technol Assess; 2010 Jul 03; 14(36):1-248. PubMed ID: 20646668
    [Abstract] [Full Text] [Related]

  • 40. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.
    Kurtoglu S, Atabek ME, Dizdarer C, Pirgon O, Isguven P, Emek S, PREDICTIVE Turkey Study Group.
    Pediatr Diabetes; 2009 Sep 03; 10(6):401-7. PubMed ID: 19220776
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.